v3.26.1
NON-CONTROLLING INTEREST
12 Months Ended
Dec. 31, 2025
Noncontrolling Interest [Abstract]  
NON-CONTROLLING INTEREST

NOTE 14 – NON-CONTROLLING INTEREST

 

On August 19, 2024, the minority shareholders in Pharmalectin, which included Company officers, exercised a conversion option for a 16.8% ownership in Bioxytran. The outstanding non-controlling interest of $855,160 was eliminated against equity.